GSK Pharmaceuticals reports a temporary production disruption due to a fire at one of its contract manufacturing facilities; ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK) has announced that a fire incident occurred at its contract manufacturing facility, resulting in temporary production disruption of ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

GSK PLC GSK shares rose 2.35% to £13.95 Friday, on what proved to be an all-around positive trading session for the stock ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.